Kairos Pharma Ltd. (NYSE American: KAPA) has been named a winner in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, receiving recognition as the USA leader in drug resistance development. The award highlights the company's work in advancing cancer therapeutics designed to address treatment resistance, underscoring Kairos' focus on extending the effectiveness of existing cancer therapies through innovative drug resistance-targeting approaches.
Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, aimed at addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
This recognition underscores the importance of addressing drug resistance in cancer treatment, a major challenge that limits the efficacy of existing therapies. By targeting CD105, Kairos Pharma's approach could potentially extend the usefulness of standard treatments, offering hope for patients who have developed resistance. The award validates the company's strategy and may attract further attention from investors and partners interested in oncology innovation.
For more information on Kairos Pharma, visit the company's newsroom at https://ibn.fm/KAPA. To view the full press release, visit https://ibn.fm/WuBOf.
